Abstract:Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curative surgical resections and tyrosine kinase inhibitors (TKIs) are the main managements for localized GISTs and recurrent/metastatic GISTs, respectively. Despite multi-lines of TKIs treatments prolonged the survival time of recurrent/metastatic GISTs by delaying the relapse and metastasis of the tumor, drug resistance developed quickly and inevitably, and became the huge obstacle for stopping disease progression. Immunotherapy, which is typically represented by immune checkpoint inhibitors (ICIs), has achieved great success in several solid tumors by reactivating the host immune system, and been proposed as an alternative choice for GIST treatment. Substantial efforts have been devoted to the research of immunology and immunotherapy for GIST, and great achievements have been made. Generally, the intratumoral immune cell level and the immune-related gene expressions are influenced by metastasis status, anatomical locations, driver gene mutations of the tumor, and modulated by imatinib therapy. Systemic inflammatory biomarkers are regarded as prognostic indicators of GIST and closely associated with its clinicopathological features. The efficacy of immunotherapy strategies for GIST has been widely explored in pre-clinical cell and mouse models and clinical experiments in human, and some patients did benefit from ICIs. This review comprehensively summarizes the up-to-date advancements of immunology, immunotherapy and research models for GIST, and provides new insights and perspectives for future studies.

[New challenges in the diagnosis and treatment of gastrointestinal stromal tumor: thinking and practice from evidence-based medicine to precision medicine].

An update on molecular genetics and drug resistance of gastrointestinal stromal tumors

[Strategies in Diagnosis and Management for Advanced or Metastatic Gastrointestinal Stromal Tumor].

Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies

Precision Oncology in Gastrointestinal Stromal Tumors

Some Hot Spots in the Treatment of Gastrointestinal Stromal Tumor

Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View

Molecular Classification and Targeted Therapy of Gastrointestinal Stromal Tumors

[Challenges of Gastrointestinal Stromal Tumor in the Era of Targeted Therapy].

Advances in Drug Therapy for Gastrointestinal Stromal Tumour

Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges

The progress and controversy on precision medicine of colorectal cancer

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Advances of endoscopic and surgical management in gastrointestinal stromal tumors

Targeted Therapy and Its Application on Gastrointestinal Stromal Tumor

Pathologic diagnosis and molecular features of gastrointestinal stromal tumors: a mini-review

Confusions and countermeasures in diagnosis and treatment of gastrointestinal stromal tumor in China

Current status and progress in novel drug research for gastrointestinal stromal tumors

[The Shift of the Treatment Strategy of Gastrointestinal Stromal Tumor from the Surgical Perspective].

[Molecular Mechanism of Gastrointestinal Stromal Tumors and Progress in Drug Research].